Am J Gastroenterol

1. YANOFSKY R, McDonald BD, Nikzad N, Choi D, et al
   Erratum to: New Eczematous Eruption in Patients With Inflammatory Bowel Disease Who Stop Janus Kinase Inhibitors.
   Am J Gastroenterol. 2026 Feb 5. doi: 10.14309/ajg.0000000000003937.
   

   >> Share

   
   
2. MOUTSOGLOU D
   Continuing Medical Education Questions: January 2026.
   Am J Gastroenterol. 2026;121:29.
   

   >> Share

   
   
3. WONG ECL, Jairath V, Dulai PS, Marshall JK, et al
   Infliximab and Upadacitinib Demonstrate Superior Early Onset of Efficacy in Biologic-Naive Ulcerative Colitis with Severe Endoscopic Disease.
   Am J Gastroenterol. 2026 Feb 2. doi: 10.14309/ajg.0000000000003940.
   

   >> Share

   
   
4. BENNETT A, Field J, Newman KL, Click B, et al
   Gender-Affirming Hormone Therapy and Risk of Inflammatory Bowel Disease Flare in Transgender and Gender Diverse Adults.
   Am J Gastroenterol. 2026;121:404-409.
   

   >> Share

   
   

   
   BMC Gastroenterol

5. METSELAAR PI, Schilder RCH, Kraneveld AD, Te Velde AA, et al
   mRNA expression of NLRP3 and IL1B in inflammatory bowel diseases: a systematic review and meta-analysis.
   BMC Gastroenterol. 2025;26:86.
   

   >> Share

   
   

   
   Clin Gastroenterol Hepatol

6. PRIVITERA G, Bezzio C, Figlioli G, D'Amico F, et al
   Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis.
   Clin Gastroenterol Hepatol. 2026 Jan 28:S1542-3565(26)00045.
   

   >> Share

   
   
7. TANG W, Jiang Z, Huang Y
   Multilocus heterotopic gastric mucosa mimicking Crohn's disease.
   Clin Gastroenterol Hepatol. 2026 Jan 30:S1542-3565(26)00049.
   

   >> Share

   
   
8. COHEN ER, Steinberg JM, Christian K
   Building and Sustaining Inflammatory Bowel Disease (IBD) Specialty Care in the Community: Insights and Solutions from the AGA IBD Community Care Initiative.
   Clin Gastroenterol Hepatol. 2026 Feb 3:S1542-3565(26)00058.
   

   >> Share

   
   
9. AGRAWAL M, Hansen AV, Julsgaard M, Colombel JF, et al
   Prediction of inflammatory bowel disease based on early life risk factors in a population-based cohort.
   Clin Gastroenterol Hepatol. 2026 Feb 3:S1542-3565(26)00063.
   

   >> Share

   
   
10. DALAL RS, Kwaning KM, Silvestri ME, Carlin AD, et al
    Comparative Effectiveness and Safety of Upadacitinib Versus Risankizumab for Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2026 Feb 3:S1542-3565(26)00061.
    

    >> Share

    
    

    
    Clin Res Hepatol Gastroenterol

11. URQUHART SA, Velasquez LEO, Kisiel JB, Coelho-Prabhu N, et al
    Clinical characteristics and outcomes of appendiceal neoplasms in inflammatory bowel disease: A tertiary care center experience.
    Clin Res Hepatol Gastroenterol. 2026;50:102778.
    

    >> Share

    
    

    
    Dig Dis Sci

12. IBRAHIM A, Rockey DC
    Clinical Outcomes in Patients with Primary Sclerosing Cholangitis With and Without Inflammatory Bowel Disease.
    Dig Dis Sci. 2026 Feb 6. doi: 10.1007/s10620-026-09699.
    

    >> Share

    
    
13. VERNON-ROBERTS A, Day AS
    Concise Commentary: Caregiver Contributions to Self-Care Among Patients with Inflammatory Bowel Disease.
    Dig Dis Sci. 2026 Feb 4. doi: 10.1007/s10620-026-09716.
    

    >> Share

    
    
14. CHANG LK, Liao CY, Lin WC, Lee CY, et al
    Incidental Appendiceal Mucocele in a Patient with Ulcerative Colitis.
    Dig Dis Sci. 2026 Jan 31. doi: 10.1007/s10620-026-09702.
    

    >> Share

    
    

    
    Gastroenterol Hepatol

15. CHEN S, Yu C, Fang F, Zhou Q, et al
    Association between sleep quality and disease activity in inflammatory bowel disease: A systematic review and meta-analysis.
    Gastroenterol Hepatol. 2026 Jan 30:502699. doi: 10.1016/j.gastrohep.2026.502699.
    

    >> Share

    
    
16. PORTA-VILARO A, Garbayo-Salmons P, Madero L, Calafat M, et al
    Complex perianal fistulas: Not everything is Crohn's Disease.
    Gastroenterol Hepatol. 2026 Jan 22:502663. doi: 10.1016/j.gastrohep.2026.502663.
    

    >> Share

    
    

    
    Gastroenterology

17. ARMET AM, Wine E
    Microbes and macrophages: how they interact to promote ulcerative colitis.
    Gastroenterology. 2026 Feb 3:S0016-5085(26)00092.
    

    >> Share

    
    
18. COWARD S, Brunet-Mas E, Burisch J, Lakatos PL, et al
    FORECASTING THE INCIDENCE AND PREVALENCE OF INFLAMMATORY BOWEL DISEASE ACROSS NINE EPIDEMIOLOGIC STAGE 3 NATIONS.
    Gastroenterology. 2026 Jan 30:S0016-5085(26)00032.
    

    >> Share

    
    

    
    Gut

19. DAI C, Huang YH, Jiang M
    Preclinical stages of Crohn's disease defined by faecal calprotectin in asymptomatic first-degree relatives.
    Gut. 2026 Feb 3:gutjnl-2026-338123. doi: 10.1136/gutjnl-2026-338123.
    

    >> Share

    
    
20. TURNER D, Kenigsberg S, Focht G, Croitoru K, et al
    Defining preclinical stages of Crohn's disease by faecal calprotectin and other risk factors: response to letter.
    Gut. 2026 Feb 3:gutjnl-2026-338188. doi: 10.1136/gutjnl-2026-338188.
    

    >> Share

    
    

    
    Inflamm Bowel Dis

21. PATEL PV, Zuniga DJ, Goyal A, Bensen R, et al
    Integrating intestinal ultrasound into routine clinical care improves prediction of biochemical disease activity in pediatric inflammatory bowel disease.
    Inflamm Bowel Dis. 2026 Feb 6:izaf337. doi: 10.1093.
    

    >> Share

    
    
22. GROS B, Orti Cuerva M, Valenzuela Garcia MA, Valdivia Krag C, et al
    Dynamic changes in clinical response to corticosteroids in ulcerative colitis.
    Inflamm Bowel Dis. 2026 Feb 5:izag002. doi: 10.1093.
    

    >> Share

    
    
23. SCHUURMAN GS, Tiel Groenestege W, Hirdes MMC, Fidder HH, et al
    Implementation of a Capillary Blood Self-Sampling Technique at Home for Monitoring of Patients With IBD.
    Inflamm Bowel Dis. 2026;32:282-289.
    

    >> Share

    
    
24. BERTIN L, Savarino EV
    Bridging the Gap: From Clinic to Home in IBD Monitoring.
    Inflamm Bowel Dis. 2026;32:404-405.
    

    >> Share

    
    
25. VALDISERRA G, Fantini MC, Favale A, Antonioli L, et al
    The Importance of Treatment Timing and Positioning in IBD.
    Inflamm Bowel Dis. 2026;32:401-403.
    

    >> Share

    
    
26. FUNG ICN, Koelink PJ, Mulders LGM, Admiraal I, et al
    Mucosal B Cell Expansion and Maturation Contribute to Colitis Pathogenesis.
    Inflamm Bowel Dis. 2026;32:290-302.
    

    >> Share

    
    
27. ARRAS W, Oosterlinck B, Gassman J, De Man JG, et al
    Clinical Significance of Mucin Signatures in Inflammatory Bowel Diseases: A Systematic Review of Their Expression Patterns, Polymorphisms, and Post-translational Modifications.
    Inflamm Bowel Dis. 2026;32:375-389.
    

    >> Share

    
    
28. SHIMODAIRA Y, Ohkubo R, Iijima K
    Repeated Administration of Carotegrast Methyl Maintained Clinical Remission With Difficult-to-Treat Ulcerative Colitis.
    Inflamm Bowel Dis. 2026;32:418-419.
    

    >> Share

    
    
29. AR E, Solomonidou I, Lenzen H, Wiestler M, et al
    Long-term clinical and endoscopic outcomes of ulcerative colitis after liver transplantation: a multicenter cohort study on the use and safety of advanced therapies.
    Inflamm Bowel Dis. 2026 Jan 30:izaf330. doi: 10.1093.
    

    >> Share

    
    
30. GOODRICH HWF, Saeed F, Dharmadhikari ND, Moran M, et al
    Frequency of computed tomography scans in Crohn's disease patients in the emergency department.
    Inflamm Bowel Dis. 2026 Jan 31:izag008. doi: 10.1093.
    

    >> Share

    
    
31. BOUTE EH, Gianolio L, Mahmmod S, Pochesci S, et al
    Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study.
    Inflamm Bowel Dis. 2026 Jan 31:izaf335. doi: 10.1093.
    

    >> Share

    
    
32. PAL P
    Steroid response in ulcerative colitis is not binary: learning from dynamic trajectories.
    Inflamm Bowel Dis. 2026 Feb 2:izag009. doi: 10.1093.
    

    >> Share

    
    
33. TOME J, Jin MF, Williams T, Tariq R, et al
    Clinical outcomes in pregnancy after ileal pouch-anal anastomosis for ulcerative colitis.
    Inflamm Bowel Dis. 2026 Feb 2:izag004. doi: 10.1093.
    

    >> Share

    
    

    
    J Crohns Colitis

34. 
    Correction to: Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis.
    J Crohns Colitis. 2026;20:jjag002.
    

    >> Share

    
    
35. HODGES P, Roberts C, Parkes M, Kennedy NA, et al
    Clinical utility of pre-treatment four-digit-resolution HLA genotyping to guide anti-tumor necrosis factor choice and concomitant immunomodulator use.
    J Crohns Colitis. 2026;20:jjaf233.
    

    >> Share

    
    

    
    J Gastroenterol

36. OSAKA R, Naito T, Khor SS, Kakuta Y, et al
    HLA-DQB1*03:01 and HLA-DQA1*05:05 as key genetic determinants of infliximab response and immunogenicity in Japanese patients with inflammatory bowel disease.
    J Gastroenterol. 2026 Feb 6. doi: 10.1007/s00535-026-02354.
    

    >> Share

    
    

    
    PLoS One

37. AOI M, Nakamura N, Honzawa Y, Fukata N, et al
    Diagnostic accuracy of endoscopic findings for cytomegalovirus reactivation in hospitalized patients with ulcerative colitis.
    PLoS One. 2026;21:e0331695.
    

    >> Share

    
    
38. ANDO K, Kashima S, Sakatani A, Konishi H, et al
    Association of tissue lymphocyte immunophenotype and clinical outcomes: A prospective study in patients with ulcerative colitis treated with vedolizumab.
    PLoS One. 2026;21:e0340271.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share